But the exact terms of the deal and the deal with Pfizer, which arrived shortly after, are still unclear. Major vaccine studies, scheduled to begin this month, will each include 30,000 people, some receiving placebo shots. The Food and Drug Administration has said that a vaccine against coronavirus should protect 50% of those who receive it to be considered effective. The goal is to produce vaccines that can end the pandemic by protecting billions of people from infections or serious diseases, and governments have signed agreements with drug manufacturers to ensure the supply of various candidates. We don`t know yet if anything will succeed. “Based on the success of clinical trials, today`s agreement will provide approximately 100 million doses of vaccines developed by Pfizer and BioNTech,” Health Minister Alex M. Azar II said in a statement announcing the deal. The agreement with Pfizer, announced Wednesday morning by the company and the Department of Health and Human Services, is the largest to date for Operation Warp Speed. The federal government announced this month that it would provide $1.6 billion to Maryland-based Novavax to accelerate the development of a coronavirus vaccine. Azar said the government began new negotiations with Pfizer in early October, but “they always refused to give us a date to do so.” He said they were making progress in their negotiations, but the government is willing to use “any power of the Defense Production Act” to get the additional Pfizer vaccine doses needed. However, not all agreements included this type of preliminary investment.
“We`ve never taken money from the U.S. government or anyone else,” kathrin Jansen, senior vice president and head of vaccine research and development at Pfizer, told the New York Times. The $1.95 billion agreement will not be paid until the government accepts the vaccines, after being approved in an emergency by the Food and Drug Administration (FDA). The contract is the largest share that the United States has spent on a vaccine, while agreements with other vaccine producers are also expected to help finance development costs. “Perhaps that is why they did not resort to this additional option agreement of 100 million euros, which would not have forced them to inject money. It was just an agreement for them to buy these vaccines,” Gottlieb said. Pfizer has therefore entered into agreements with other countries to sell part of this vaccine to them in the second quarter of 2021. On Monday, Pfizer and AstraZeneca, a British-Swedish pharmaceutical company that is developing a potential vaccine with Oxford University, released data suggesting their vaccines could stimulate powerful immune responses with low side effects. The conclusion of this agreement allows a safe and effective vaccine to be quickly shipped if the FDA licenses the ERA.